Literature DB >> 11008011

The thin red line: angiogenesis in normal and malignant hematopoiesis.

F Bertolini1, P Mancuso, A Gobbi, G Pruneri.   

Abstract

This review describes the current knowledge about cell subsets involved in vasculogenesis (i.e., differentiation of endothelial cells from mesodermal precursors) and angiogenesis (i.e., blood vessel generation from pre-existing vessels), together with recent findings about angiogenesis and antiangiogenic therapies in hematopoietic malignancies such as leukemia, lymphoma, myeloma, and myelodysplastic syndromes.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11008011     DOI： 10.1016/s0301-472x(00)00508-7

Source DB:  PubMed          Journal:  Exp Hematol        ISSN： 0301-472X            Impact factor:   3.084


  9 in total

1.  Serial morphologic observation of bone marrow in aplastic anemia in children.

Authors:  Fumio Bessho; Shinsaku Imashuku; Shigeyoshi Hibi; Masahiro Tsuchida; Tatsutoshi Nakahata; Sumio Miyazaki; Seiji Kojima; Ichiro Tsukimoto; Nobuyuki Hamajima
Journal:  Int J Hematol       Date:  2005-06       Impact factor: 2.490

2.  [Therapy-related changes of angiogenesis in Philadelphia chromosome positive chronic myelogenous leukemia].

Authors:  H M Kvasnicka; J Thiele; P Staib; K Engels; S Kriener; A Schmitt-Graeff
Journal:  Pathologe       Date:  2004-03       Impact factor: 1.011

3.  Microvessel density, endothelial-cell proliferation and carbonic anhydrase IX expression in haematological malignancies, bone-marrow metastases and monoclonal gammopathy of undetermined significance.

Authors:  H R De Raeve; P B Vermeulen; K Vanderkerken; A L Harris; E Van Marck
Journal:  Virchows Arch       Date:  2004-05-28       Impact factor: 4.064

4.  Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group.

Authors:  Rena Buckstein; John Kuruvilla; Neil Chua; Christina Lee; David A Macdonald; Abdulwahab J Al-Tourah; Alison H Foo; Wendy Walsh; S Percy Ivy; Michael Crump; Elizabeth A Eisenhauer
Journal:  Leuk Lymphoma       Date:  2011-04-04

5.  Murine 5T multiple myeloma cells induce angiogenesis in vitro and in vivo.

Authors:  E Van Valckenborgh; H De Raeve; L Devy; S Blacher; C Munaut; A Noël; E Van Marck; I Van Riet; B Van Camp; K Vanderkerken
Journal:  Br J Cancer       Date:  2002-03-04       Impact factor: 7.640

6.  Anti-myeloma effect of pharmacological inhibition of Notch/gamma-secretase with RO4929097 is mediated by modulation of tumor microenvironment.

Authors:  Alexandra Pisklakova; Eileen Grigson; Maria Ozerova; Feng Chen; Daniel M Sullivan; Yulia Nefedova
Journal:  Cancer Biol Ther       Date:  2016-03-02       Impact factor: 4.742

7.  Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia.

Authors:  Joanna Gora-Tybor; Jerzy Z Blonski; Tadeusz Robak
Journal:  Mediators Inflamm       Date:  2003-06       Impact factor: 4.711

8.  Phase II testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182-185.

Authors:  R Buckstein; R M Meyer; L Seymour; J Biagi; H Mackay; S Laurie; E Eisenhauer
Journal:  Curr Oncol       Date:  2007-08       Impact factor: 3.677

9.  Antiangiogenic gene therapy of cancer: recent developments.

Authors:  Anita Tandle; Dan G Blazer; Steven K Libutti
Journal:  J Transl Med       Date:  2004-06-25       Impact factor: 5.531
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.